Solid Neoplasm Clinical Trial
Official title:
Phase I Study of Tivantinib Plus Bevacizumab
This phase I trial studies the side effects of and best dose of tivantinib when given together with bevacizumab in treating patients with solid tumors that have spread to other areas of the body or cannot be removed by surgery. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving tivantinib together with bevacizumab may work better in treating tumor cells.
PRIMARY OBJECTIVES:
I. Determine the recommended phase II dose (RP2D) of the vascular endothelial growth factor
(VEGF) monoclonal antibody, bevacizumab in combination with the allosteric met proto-oncogene
(MET) inhibitor, tivantinib, in patients with advanced solid tumors.
SECONDARY OBJECTIVES:
I. Describe the dose-limiting toxicity (DLT) and other toxicities associated with bevacizumab
in combination with tivantinib as assessed by Common Terminology Criteria for Adverse Events
(CTCAE) version (v) 4.0.
II. Document anti-tumor activity of bevacizumab in combination with tivantinib in patients
with advanced solid tumors.
III. Determine the pharmacokinetics of tivantinib when administered in combination with
bevacizumab in patients with advanced solid tumors.
IV. Perform cytochrome P450 family 2, subfamily C, polypeptide 19 (CYP2C19) genotyping on all
subjects and correlate with pharmacokinetics and toxicity.
V. Assess the effect of bevacizumab plus tivantinib on plasma components of the
hepatocellular growth factor (HGF)-MET signaling pathway (HGF, HGF activator [HGFA]) and VEGF
signaling pathway (VEGF A, B, C, D and placental growth factor [PIGF]).
VI. Assess tissue (tumor and skin) protein biomarkers before and after study treatment
including MET, phospho-MET^tyrosine (Tyr)1349 and phosphor-focal adhesion kinase
(FAK)^Tyr861.
VII. Assess early therapy response by quantitative biomarker imaging fludeoxyglucose F 18
(F-18 FDG) positron emission tomography (PET) and magnetic imaging resonance (MRI) on a
smaller sample (n up to 15) of subjects willing to participate in the imaging assessment
through UPCI 12-096.
OUTLINE: This is a dose-escalation study of tivantinib.
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days -15, 1, and 15
(day -15 of course 1 only) and tivantinib orally (PO) twice daily (BID) on days 1-28. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02540876 -
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
|
Phase 1 | |
| Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
| Active, not recruiting |
NCT03834961 -
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
|
Phase 2 | |
| Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01017640 -
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Completed |
NCT03775616 -
Financial Navigation Program Intervention in Supporting Patients With Solid Tumors and Their Caregivers
|
N/A | |
| Active, not recruiting |
NCT03098277 -
Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
|
N/A | |
| Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
| Terminated |
NCT02414724 -
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT02876068 -
Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00085553 -
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
| Recruiting |
NCT03023202 -
UWCCC Molecular Tumor Board Registry
|
||
| Active, not recruiting |
NCT02706366 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01552356 -
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
| Completed |
NCT02360215 -
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
|
Phase 3 | |
| Withdrawn |
NCT03804255 -
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
|